Allogene Therapeutics Inc
NASDAQ:ALLO

Watchlist Manager
Allogene Therapeutics Inc Logo
Allogene Therapeutics Inc
NASDAQ:ALLO
Watchlist
Price: 1.4 USD 2.94% Market Closed
Market Cap: 314.6m USD

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of ALLO.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ALLO Intrinsic Value
Not Available
Base Case Scenario
Compare ALLO to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about ALLO?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Allogene Therapeutics Inc

Current Assets 260.7m
Cash & Short-Term Investments 252.2m
Receivables 2.1m
Other Current Assets 6.4m
Non-Current Assets 179.1m
Long-Term Investments 24.9m
PP&E 116.8m
Other Non-Current Assets 37.3m
Current Liabilities 31.8m
Accounts Payable 3.7m
Accrued Liabilities 28.1m
Non-Current Liabilities 92.6m
Other Non-Current Liabilities 92.6m
Efficiency

Free Cash Flow Analysis
Allogene Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Allogene Therapeutics Inc

Revenue
0 USD
Operating Expenses
-225m USD
Operating Income
-225m USD
Other Expenses
13m USD
Net Income
-212m USD
Fundamental Scores

ALLO Profitability Score
Profitability Due Diligence

Allogene Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Negative 3Y Average Net Margin
Declining ROE
Negative 3Y Average Operating Margin
19/100
Profitability
Score

Allogene Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

ALLO Solvency Score
Solvency Due Diligence

Allogene Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
59/100
Solvency
Score

Allogene Therapeutics Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ALLO Price Targets Summary
Allogene Therapeutics Inc

Wall Street analysts forecast ALLO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ALLO is 7.71 USD with a low forecast of 1.62 USD and a high forecast of 14.7 USD.

Lowest
Price Target
1.62 USD
15% Upside
Average
Price Target
7.71 USD
451% Upside
Highest
Price Target
14.7 USD
950% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Allogene Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ALLO is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

ALLO Insider Trading
Buy and sell transactions by insiders